Navigation Links
CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer
Date:2/27/2009

re inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug development candidates and programs.

Additional Information

Stockholders of CV Therapeutics are advised to read CV Therapeutics' Schedule 14D-9 statement, when it becomes available, regarding the tender offer, because it will contain important information. Stockholders may obtain a free copy of the statement at the SEC's website at www.sec.gov. Stockholders may also obtain, without charge, a copy of the statement from MacKenzie Partners, Inc., which is assisting the company, by calling 800-322-2885 toll free or by calling 212-929-5500 or by emailing cvtx@mackenziepartners.com.

Except for the historical information contained herein, the matters set forth in this press release, including statements as to research and development and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-K for the year ended December 3
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , September 29, 2014 Atox ... severe infections, today announced that the Biomedical Advanced Research ... Bio with a contract valued up to $24 million ... treat Necrotizing Soft Tissue Infections (NSTI) and potentially infections ... in sepsis. BARDA awarded the contract to ...
(Date:9/29/2014)... , Sept. 29, 2014  Xcenda, the strategic ... global pharmaceutical sourcing and distribution service companies, recently ... consumption. This research was analyzed in an economic ... associated with an increase in life years and ... at population-level coffee consumption across the ...
(Date:9/28/2014)... Modality Solutions, a company ... highly regulated industries, is pleased to announce Consulting ... Transport Simulation Laboratoryâ„¢ software at the 12th Annual ... Forum in Boston, September 29 through October 3. ... software on October 2, day two of the ...
(Date:9/27/2014)... available in German . ... only used for precisely surveying the surface topology of ... is done by exciting the atoms to fluoresce under ... This secondary emission provides information about the location and ... precise. However, the lighter elements of the periodic table ...
Breaking Biology Technology:Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 2Coffee Consumption May Increase Survival and Reduce Healthcare Costs 3Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 2Consulting Engineer Brian Brazill to Demonstrate Modality Solutions Advantage Transport Simulation Laboratory Software at 12th Annual Cold Chain Global Forum 3'Multi-spectra glasses' for scanning electron microscopy 2
... Pharmaceuticals,Inc. (NYSE: BRL ) today confirmed that ... of the patents listed by Amgen Inc. in,connection ... 90mg., Barr,s Abbreviated New Drug Application (ANDA) ... product was received as acceptable,for filing by the ...
... are to be used in clinical trials ... on a path to finally cure diabetes, ... recently declared its commitment to support Spring Point,Project, a Minnesota non-profit ... of islet tissue for,diabetes care., (Logo: http://www.newscom.com/cgi-bin/prnh/20071214/CLF057LOGO-b ), ...
... as an Antipsychotic Agent with Less Potential for ... Weight Gain and Metabolic Risks, SAN DIEGO, July ... announced that the United States Patent and,Trademark Office (USPTO) ... would provide broad coverage for a pharmaceutical,composition of zonisamide ...
Cached Biology Technology:Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg 2Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg 3Spring Point Project Gains Support of Lions Clubs 2Spring Point Project Gains Support of Lions Clubs 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 2OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 3OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003 4
(Date:9/29/2014)... order to support the world,s needs to make ... more, new and more efficient catalytic materials and ... including several from Wayne State University, is tackling ... grant from the National Science Foundation. , The ... Multicomponent Materials for Electrocatalytic Cascade Reactions," was to ...
(Date:9/29/2014)... received a five-year, $6 million grant for clinical ... and development of safe and effective treatments for ... the National Institutes of Health, National Institute on ... Medication Development for Cocaine Use Disorder to oversee ... decisions on moving forward with more expensive large-scale ...
(Date:9/29/2014)... review article published online in Behavioral Brain Research ... the brain as a result of chronic alcohol exposure ... , Clinical assessments and research indicate that individuals ... sleep. This can occur when people are actively drinking, ... are abstaining. , "Sleep-wake disturbances can last for ...
Breaking Biology News(10 mins):Wayne State research aims to develop new, more efficient catalytic materials 2New VCU center to target cocaine addiction 2
... 14, 2012 The latest episode in the American ... podcast series describes the development of a new test ... Amid concerns about the threat of terrorist attacks, ... and other nations. One such team has developed a ...
... Irvine researchers have discovered how Salmonella , a bacterium ... in humans, thrives in the digestive tract despite the immune ... explain why Salmonella is difficult to eradicate and ... with Salmonella suffer from diarrhea, fever and abdominal ...
... A parking lot at the edge of the University ... emerging concern for the environment and human health. ... journal Environmental Science & Technology , has found that ... lots throughout the nation, has significant health and ecosystem implications. ...
Cached Biology News:New test could help track down and prosecute terrorists 2UCI-led study uncovers how Salmonella avoids the body's immune response 2UNH research adds to mounting evidence against popular pavement sealcoat 2